Review article: The need for more efficient and patient‐oriented drug development pathways in NASH—setting the scene for platform trials
暂无分享,去创建一个
F. Tacke | Q. Anstee | J. Genescà | V. Ratziu | R. Pais | J. Pericàs | R. Manzano | N. D. Di Prospero | M. Kjaer | Elena Sena | Peter Mesenbrinck | Franz Koenig | J. Rivera‐Esteban
[1] F. Tacke,et al. Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons. , 2022, Journal of hepatology.
[2] Marta Bofill Roig,et al. On model-based time trend adjustments in platform trials with non-concurrent controls , 2021, BMC Medical Research Methodology.
[3] A. Khosla,et al. A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH , 2021, Hepatology.
[4] M. Desai,et al. Clinical trials in a COVID-19 pandemic: Shared infrastructure for continuous learning in a rapidly changing landscape , 2021, Clinical trials.
[5] A. Sanyal,et al. Development of a Patient-Reported Outcome Measure for Non-Alcoholic Steatohepatitis (NASH-CHECK): Results of a Qualitative Study , 2020, The Patient - Patient-Centered Outcomes Research.
[6] R. Ritchie,et al. Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments , 2020, Frontiers in Pharmacology.
[7] M. Allison,et al. The European NAFLD registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. , 2020, Contemporary clinical trials.
[8] P. Bedossa,et al. An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials , 2020, Diagnostics.
[9] M. Posch,et al. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. , 2020, Clinical therapeutics.
[10] G. Koch,et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. , 2020, Journal of hepatology.
[11] V. Miller,et al. Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations from the Liver Forum. , 2020, Journal of hepatology.
[12] T. Okanoue,et al. Current and new pharmacotherapy options for non-alcoholic steatohepatitis , 2020, Expert opinion on pharmacotherapy.
[13] F. Beyer,et al. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis , 2020, JHEP reports : innovation in hepatology.
[14] V. Wong,et al. Selonsertib for Patients with Bridging Fibrosis or Compensated Cirrhosis Due to NASH: Results from Randomized Ph III STELLAR Trials. , 2020, Journal of hepatology.
[15] N. Bhala,et al. Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.
[16] M. Sydes,et al. Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement , 2020, British Journal of Cancer.
[17] A. Tzallas,et al. High-Throughput, Machine Learning–Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[18] H. Conjeevaram,et al. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients with Nonalcoholic Steatohepatitis With Cirrhosis And Portal Hypertension. , 2019, Gastroenterology.
[19] F. Tacke,et al. New drugs for NAFLD: lessons from basic models to the clinic , 2019, Hepatology International.
[20] Hongliang Li,et al. Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease , 2019, Trends in Endocrinology & Metabolism.
[21] F. Tacke,et al. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD , 2019, Hepatology.
[22] Karl Broich,et al. Master protocols in clinical trials: a universal Swiss Army knife? , 2019, The Lancet. Oncology.
[23] D. Rockey,et al. Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. , 2018, Gastroenterology.
[24] B. Neuschwander‐Tetri,et al. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science , 2017, Hepatology.
[25] J. Woodcock,et al. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. , 2017, The New England journal of medicine.
[26] Robert Blissett,et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe , 2016, Hepatology.
[27] S. Berry,et al. Efficiencies of platform clinical trials: A vision of the future , 2016, Clinical trials.
[28] D. Berry,et al. Emerging innovations in clinical trial design , 2016, Clinical pharmacology and therapeutics.
[29] S. Friedman,et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop , 2015, Hepatology.
[30] B. Neuschwander‐Tetri,et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.
[31] V. Wong,et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease , 2020 .